JPRN-UMIN000019735已完成未知
Examination the efficacy of Mirabegron on patient with overactive bladder after treatment with a1 blocker for benign prostatic hyperplasia - Examination the efficacy of Mirabegron on patient with a1 blocker resistance overactive bladder
Department of Urology, Shiga University of medical Science0 个研究点目标入组 20 人开始时间: 2015年11月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •suspect of malignancy contraindication of Mirabegron using other anticholinergic agent using A1 blocker within 4 weeks using Dutasteride redidual urine over 50mL urinary infection
研究者
相似试验
尚未招募
4 期
Comparing the efficacy of Mirabegron in reducing urinary symptoms associated with cerebrovascular accidentsCTRI/2023/03/050511DEPARTMENT OF UROLOGY KASTURBA MEDICAL COLLEGE MANIPA
尚未招募
4 期
Comparing the efficacy of Mirabegron in reducing urinary symptoms associated with Parkinsons diseaseCTRI/2023/01/048770DEPARTMENT OF UROLOGY KASTURBA MEDICAL COLLEGE MANIPA
进行中（未招募）
不适用
Miro-CensPeripheral Neuropathic Pain caused by Cervical Spondylotic RadiculopathyJPRN-jRCTs031210629Hirai Takashi140
已完成
4 期
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)Overactive BladderNCT02656173Astellas Pharma Inc568
已完成
4 期
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)Overactive Bladder (OAB)NCT02216214Astellas Pharma Global Development, Inc.888